Cotinga Pharmaceuticals Vállalati érték
Mi az Cotinga Pharmaceuticals Vállalati érték?
A Vállalati érték az Cotinga Pharmaceuticals, Inc. - $1.07M
Mi a Vállalati érték meghatározása?
A vállalati érték a vállalat teljes piaci értékének mértéke. A piaci kapitalizáció az adósság, a kisebbségi részesedés és a preferált részvények összege, a pénzeszközök és pénzeszköz-egyenértékek összege mínusz.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Vállalati érték a Health Care szektor a TSXV-on cégekben a Cotinga Pharmaceuticals -hoz képest
Mit csinál Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
vállalati érték -hoz hasonló cégek Cotinga Pharmaceuticals
- Core Canadian Dividend Trust nak Vállalati érték $1.04M van
- Q Technology nak Vállalati érték $1.05M van
- Predictiv AI nak Vállalati érték $1.06M van
- Orestone Mining nak Vállalati érték $1.06M van
- RNY Property Trust nak Vállalati érték $1.06M van
- Zinc One Resources nak Vállalati érték $1.06M van
- Cotinga Pharmaceuticals nak Vállalati érték $1.07M van
- Thred nak Vállalati érték $1.07M van
- BPM Minerals nak Vállalati érték $1.07M van
- Roots Sustainable Agricultural Technologies nak Vállalati érték $1.07M van
- Immobiliere Distri-Land NV nak Vállalati érték $1.07M van
- Pangolin Diamonds nak Vállalati érték $1.08M van
- Vintana Plc nak Vállalati érték $1.09M van